Drug Profile
Research programme: targeted cancer therapeutics - NantBioScience
Latest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator NantBioScience
- Class Albumins
- Mechanism of Action KRAS protein inhibitors; P53 gene modulators; Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 28 Feb 2018 No recent reports of development identified for preclinical development in Cancer in USA
- 13 Jan 2014 Preclinical trials in Cancer in USA (unspecified route)